Information Provided By:
Fly News Breaks for October 23, 2015
ABBV
Oct 23, 2015 | 08:22 EDT
JPMorgan analyst Chris Schott expects the FDA warning letter to impact Viekira sales but says the 10% pullback yesterday in shares of AbbVie looks overdone. Longer term expectations for Viekira are already "very low" while the company has "several more compelling products" in development, Schott tells investors in a research note. He keeps an Overweight rating on AbbVie.
News For ABBV From the Last 2 Days
There are no results for your query ABBV